Extrait

Background and study aims Cytomegovirus CMV) is a common virus belonging to the herpes family. It is spread though bodily fluids and can be oassed on though close contact. Most cases do not cause symptoms, but it can cause flu-like symptoms and weaken the immune system. Research is currently underway to develop vaccines for CMV. It is possible that these transplants may reactivate an existing CMV infection in the recipient. This carries with it a high risk of disease and death. The aim of this study is to test a novel vaccine for patients that have a stem cell transplantation. To see whether it results in an effective immune response against the infection and therefore preventing it. Who can participate? Patients about to undergo a bone marrow transplant and are at high risk of CMV reactivation. What does the study involve? Participants are given 4 doses of the new vaccine (CMVpp65 peptide vaccine) every two weeks after their transplantation. They are examined for any CMVV infection throughout with the final examination nine weeks after the first vaccination. What are the possible benefits and risks of participating? Not provided at time of registration Where is the study run from? University of Ulm, Department of Internal Medicine III (Germany) When is the study starting and how long is it expected to run for? June 2011 to April 2015 Who is funding the study? Federal Ministry of Education and Research, BMBF (Gernany) Who is the main contact? 1. Professor Michael Schmitt (scientific) [email protected] 2. Professor Jochan Greiner (scientific) [email protected]

Critère d'inclusion

• Cytomegalovirus (CMV)

Liens

• ictrp
• isrctn